A prospective pilot study on serum cleaved tau protein as a neurological marker in severe traumatic brain injury.

Objective: Neurotrauma has been labelled as a "silent epidemic" affecting both the developed and the developing nations. To date, no single brain-specific biomarker has been unanimously accepted for routine clinical use in TBI. Our study aims to determine the correlation of "cleaved-tau protein" in severe traumatic brain injury (TBI) with Glasgow Coma Scale (GCS) at the time of admission, mode of injury, CT findings and outcome at discharge. Methods: The study has been approved by the institutional ethical committee. 40 cases with severe TBI and 40 randomly selected healthy controls were included in this prospective study. Venous blood samples were collected and serum cleaved tau protein levels were measured and correlated with gender, mode of injury, CT findings GCS score and GOS score at discharge. Results: In the severe TBI group, the mean serum cleaved tau protein levels in males were 91.65 +/- 41.34 pg/ml (mean +/- S. D.), and females were 104.43 +/- 53.08 pg/ml (mean +/- S. D.), (p = 0.27). Mean serum C-tau level in study group was 95.48 +/- 44.87 pg/ml (range 36.44-192.34), 95% C. I. (81.13-109.83) and in controls was 33.82 +/- 13.65 pg/ml (range 2.48-66.54), 95% C. I. (29.46-38.19) (p< 0.001). The distribution of serum C-tau was in severe TBI group varied in all categories of GCS at 0th day (p< 0.001). Serum cleaved tau protein levels in the good outcome group were 74.26 +/- 25.43 pg/ml (mean +/- S. D.), range 36.44-144.54, 95% C. I. (63.52-85.00) and the poor-outcome group were 127.32 +/- 49.40 pg/ml, range 66.65-192.34, 95% C. I. (100.99-153.64) (p = 0.001). Conclusion: In severe TBI, serum cleaved tau protein levels were significantly higher as compared to the controls in this prospective study. However, results of this study are preliminary in nature and there is a need to undertake larger prospective studies to reach a definitive conclusion.